161 related articles for article (PubMed ID: 9746605)
1. Localization of a T-cell epitope of superantigen toxic shock syndrome toxin 1 to residues 125 to 158.
Hu WG; Zhu XH; Wu YZ; Jia ZC
Infect Immun; 1998 Oct; 66(10):4971-5. PubMed ID: 9746605
[TBL] [Abstract][Full Text] [Related]
2. V beta specificity of superantigen TSST-1 plus CD28 costimulation without APCs.
Hu WG; Zhu XH
Immunol Invest; 1996; 25(5-6):405-11. PubMed ID: 8915678
[TBL] [Abstract][Full Text] [Related]
3. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin-1 to T cells.
Hogan RJ; VanBeek J; Broussard DR; Surman SL; Woodland DL
J Immunol; 2001 Jun; 166(11):6514-22. PubMed ID: 11359802
[TBL] [Abstract][Full Text] [Related]
4. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1.
Buonpane RA; Moza B; Sundberg EJ; Kranz DM
J Mol Biol; 2005 Oct; 353(2):308-21. PubMed ID: 16171815
[TBL] [Abstract][Full Text] [Related]
5. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig.
Saha B; Jaklic B; Harlan DM; Gray GS; June CH; Abe R
J Immunol; 1996 Nov; 157(9):3869-75. PubMed ID: 8892617
[TBL] [Abstract][Full Text] [Related]
6. Patterns of interferon-gamma mRNA expression in toxic shock syndrome toxin-1 expanded V beta 11+ T lymphocytes.
Zhao YX; Abdelnour A; Ljungdahl A; Olsson T; Tarkowski A
Cell Immunol; 1995 Mar; 161(1):28-33. PubMed ID: 7867082
[TBL] [Abstract][Full Text] [Related]
7. Delineation by use of specific monoclonal antibodies of the T-cell receptor and major histocompatibility complex interaction sites on the superantigen toxic shock syndrome toxin 1.
Shimonkevitz R; Boen E; Malmstrom S; Brown E; Hurley JM; Kotzin BL; Matsumura M
Infect Immun; 1996 Apr; 64(4):1133-9. PubMed ID: 8606069
[TBL] [Abstract][Full Text] [Related]
8. Vbeta-restricted T cell adherence to endothelial cells: a mechanism for superantigen-dependent vascular injury.
Brogan PA; Shah V; Klein N; Dillon MJ
Arthritis Rheum; 2004 Feb; 50(2):589-97. PubMed ID: 14872503
[TBL] [Abstract][Full Text] [Related]
9. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
von Bonin A; Ehrlich S; Malcherek G; Fleischer B
Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
[TBL] [Abstract][Full Text] [Related]
10. Staphylococcal toxin-induced T cell proliferation in atopic eczema correlates with increased use of superantigen-reactive Vbeta-chains in cutaneous lymphocyte-associated antigen (CLA)-positive lymphocytes.
Davison S; Allen M; Vaughan R; Barker J
Clin Exp Immunol; 2000 Aug; 121(2):181-6. PubMed ID: 10931129
[TBL] [Abstract][Full Text] [Related]
11. Protection against lethal toxic shock by targeted disruption of the CD28 gene.
Saha B; Harlan DM; Lee KP; June CH; Abe R
J Exp Med; 1996 Jun; 183(6):2675-80. PubMed ID: 8676089
[TBL] [Abstract][Full Text] [Related]
12. Recombinant expression and neutralizing activity of an MHC class II binding epitope of toxic shock syndrome toxin-1.
Rubinchik E; Chow AW
Vaccine; 2000 Apr; 18(21):2312-20. PubMed ID: 10717352
[TBL] [Abstract][Full Text] [Related]
13. A quantitative real time PCR method to analyze T cell receptor Vbeta subgroup expansion by staphylococcal superantigens.
Seo KS; Park JY; Terman DS; Bohach GA
J Transl Med; 2010 Jan; 8():2. PubMed ID: 20070903
[TBL] [Abstract][Full Text] [Related]
14. Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells.
Wen R; Broussard DR; Surman S; Hogg TL; Blackman MA; Woodland DL
Eur J Immunol; 1997 Mar; 27(3):772-81. PubMed ID: 9079821
[TBL] [Abstract][Full Text] [Related]
15. Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1.
Rukkawattanakul T; Sookrung N; Seesuay W; Onlamoon N; Diraphat P; Chaicumpa W; Indrawattana N
Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28218671
[TBL] [Abstract][Full Text] [Related]
16. Endogenous superantigens shape response to exogenous superantigens.
Rajagopalan G; Singh M; Sen MM; Murali NS; Nath KA; David CS
Clin Diagn Lab Immunol; 2005 Sep; 12(9):1119-22. PubMed ID: 16148182
[TBL] [Abstract][Full Text] [Related]
17. Accelerated induction of experimental allergic encephalomyelitis in PL/J mice by a non-V beta 8-specific superantigen.
Soos JM; Hobeika AC; Butfiloski EJ; Schiffenbauer J; Johnson HM
Proc Natl Acad Sci U S A; 1995 Jun; 92(13):6082-6. PubMed ID: 7541140
[TBL] [Abstract][Full Text] [Related]
18. Immune response to staphylococcal superantigens.
Krakauer T
Immunol Res; 1999; 20(2):163-73. PubMed ID: 10580640
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1.
Acharya KR; Passalacqua EF; Jones EY; Harlos K; Stuart DI; Brehm RD; Tranter HS
Nature; 1994 Jan; 367(6458):94-7. PubMed ID: 8107781
[TBL] [Abstract][Full Text] [Related]
20. The T cell receptor beta-chain second complementarity determining region loop (CDR2beta governs T cell activation and Vbeta specificity by bacterial superantigens.
Nur-ur Rahman AK; Bonsor DA; Herfst CA; Pollard F; Peirce M; Wyatt AW; Kasper KJ; Madrenas J; Sundberg EJ; McCormick JK
J Biol Chem; 2011 Feb; 286(6):4871-81. PubMed ID: 21127057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
